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ABSTRACT
Background: In our previous study we found that half of the patients treated at the Nylon 
District Hospital tuberculosis (TB) treatment centre were seropositive. HIV does not 
only fuel the number of tuberculosis (TB) cases worldwide but it is also at least in part, 
responsible for the non-achievement of the 85% cure rate target. 
Objective: To compare the TB treatment outcome of Smear Positive Pulmonary tuberculosis 
(SPPT) patients who did an HIV test and those who refused the test as well as compare the 
treatment outcomes between the HIV positive and HIV negative SPPT patients from 2003 
to 2005, all of whom were treated as outpatients under routine programme conditions. 
Design: A retrospective study.  
Subjects: Four hundred and twenty patients were registered from 2003 to 2005 as having 
SPPT.
Setting: The Nylon District Hospital, Cameroon.
Results: Thirty five point two per cent of the 386 SPPT patients also had HIV. The overall 
cure rate, default rate and death rate were 69%, 23.6% and 3.3% respectively. SPPT/HIV 
co-infected patients were significantly more likely to default from treatment (28.7% 
versus 16.8%, OR 1.943, 95%CI 1.150-3.285) to die in the course of treatment (7.4% versus 
0.4%, OR 23.714, 95%CI 2.894-194.330) or not to be cured (58.8% versus 78.8%, OR 0.404, 
95%CI 0.250-0.652) compared to SPPT/HIV negative patients. Likewise SPPT patients 
not tested for HIV were significantly less cured (38.2% versus 71.8%, OR 0.21, 95%CI 
0.099-0.445) and defaulted most (52.9% versus 21%, OR 4.773 95%CI 2.281-9.991) compared 
to SPPT patients tested for HIV. 
Conclusion: SPPT patients infected with HIV or not tested for HIV in the course of TB 
treatment are likely to suffer from unfavorable treatment outcomes. Thus health personnel 
prescribing anti- TB drugs should be provided with the necessary expertise to diagnose 
and manage HIV so that TB/HIV co-infected patients benefit from an integrated package 
of care in and out of the hospital. 
INTRODUCTION
Tuberculosis (TB) disease remains a public health 
problem worldwide especially in Africa and Asia. 
Before the advent of Human Immunodeficiency 
Virus/Acquired Immunodeficiency Syndrome 
(HIV/AIDS), relatively low disease burden levels 
were attained by many countries as a result of better 
treatment outcome. HIV has not only been blamed 
for the alarming increase of TB cases worldwide 
but has also been accused of being responsible for 
the non achievement of the 85% cure rate target for 
identified TB cases set by World Health Organisation 
(WHO) and International Union for the fight Against 
Tuberculosis and Lung Diseases (IUATLD) (1-3). 
 While some studies found comparable TB cure 
rates among HIV positive and HIV negative patients 
(4,5), others have reported lower cure rates among TB 
patients infected with HIV(6,7). On the other hand, 
higher case fatalities have unanimously been reported 
in TB/HIV co-infected patients (4-9). The risk of death 
in HIV positive patients presenting with TB disease 
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is approximately four times higher than that of HIV 
negative TB patients (10). During the initial phase of 
TB treatment, the cause of death might be due to TB 
but after the intensive phase of treatment it is usually 
due to other HIV related complications (4). The one 
year mortality rate of TB patients infected with HIV 
ranges from 20-35% (11). 
 The impact of HIV on TB treatment outcome in 
Cameroon is worth to be analysed most especially 
as the incidence and prevalence of HIV remains 
high. In 2004, the national programme for the fight 
against TB reported that 40% of patients with smear 
positive pulmonary tuberculosis (SPPT) were HIV 
positive (12). 
 The Nylon District Hospital (NDH) with 
its pioneer HIV/AIDS treatment programme 
(PREvention et Traitement Intégré du VIh- PRETIVI 
Project) set up by Médecin Sans Frontiéres/
Switzerland (MSF-CH) and a TB treatment and 
diagnosis centre provides an ideal setting for the 
evaluation of the impact of HIV on TB treatment 
outcome at district level. In this study we compare 
the TB treatment outcome of SPPT patients who did 
an HIV test and those who refused the test as well 
as compare the treatment outcome between the HIV 
positive and HIV negative SPPT patients from 2003 
to 2005, all of whom were treated as outpatients 
(self-administered drugs) under routine programme 
conditions. Our findings will provide information 
on the adequacy of the present treatment strategy as 
per the National Tuberculosis Programme, at district 
hospitals or health centre levels where treatment is 
not daily supervised at least for the intensive phase 
of therapy, in a country with high HIV burden. 
MATERIALS AND METHODS
Setting: The Nylon District Hospital is a first line 
referral unit in the Nylon Health District. It also 
co-habits an HIV/AIDS (PRETIVI) project and a 
TB diagnosis and treatment centre since 2001. The 
PRETIVI project was the first of its kind in the Littoral, 
South West and West regions of Cameroon with over 
six million inhabitants providing comprehensive care 
to Persons Living With HIV/AIDS (PL W HIV/AIDS) 
at district level. The integration of both TB and HIV 
programmes gave the hospital a good reputation and 
attracted a lot of patients. 
 Case detection of tuberculosis is essentially 
passive. Patients who consulted at the hospital with 
a dry or productive cough for more than or equal to 
three weeks with or without chest pain, dyspnoea, 
haemoptysis, fever, night sweats, weight loss were 
requested to do a sputum test (three early morning 
sputum smear in three days). Patients with at least 
two of the three sputum smear positive for acid fast 
bacilli were declared SPPT and those who had never 
taken TB medications were considered as new cases. 
 Following the national guidelines (12) over the 
said period, new cases of SPPT were treated with 
Rifampicine, Isoniazid, Ethambutol and Pyrazinamide 
(RHEZ) for two months followed by Rifampicine 
and Isoniazid (RH) for four months on daily basis 
(2RHEZ/4RH). Relapse sputum smear positive cases 
(due to treatment failure, defaulting or re-treatment) 
were treated with Rifampicine, Isoniazid, Ethambutol 
Pyrazinamide and Streptomycine (RHEZS) for two 
months then RHEZ for one month followed by 
Rifampicine, Isoniazid and Ethambutol (RHE) thrice 
a week for five months (2RHEZS/lRHEZ/5{RH3E3}). 
Sputum control exams were done for all patients 
with a positive smear TB at the end of the second 
(third month for relapse cases) and fifth months of 
treatment. 
 HIV test was done in the hospital laboratory 
on daily basis to patients after precounselling at the 
psychosocial department. Rapid antibody testing 
techniques were used in the following pairs with respect 
to the availability: Determine® HIV-1/2 test (ABBOT 
Diagnostic Division, Hoofddorp, Netherlands) and 
Immunocomb II Bispot HIV-l/2 (Orgenetics Ltd, 
Israel) or Determine® HIV-l/2 test (ABBOT Diagnostic 
Division, Hoofddorp, Netherlands) and Camstix HIV 
l/2 (Camdiagnostix, Yaounde, Cameroon). A person 
was considered HIV positive  if  both tests were positive. 
Once the first test (Determine®) was negative, a second 
test was not done. Indeterminate results were sent 
to the Centre Pasteur Laboratory in Yaounde for a 
confirmatory test and the results made known to the 
patients when available. The results were given to the 
patients from the 48th hour after post-counselling by 
workers in the psychosocial department. HIV positive 
patients were automatically proposed to join the 
PRETIVI Project during post-counselling. A PRETIVI 
file was opened for patients with a positive response 
and he/she referred for medical consultation. 
 The definitions used for treatment outcome by the 
national guideline are similar to those recommended 
by WHO and the IUATLD. Treatment outcome was 
determined after six months for patients with new 
SPPT and after eight months for relapse cases. In this 
study the following operational definitions for the 
given treatment outcome variable were used: 
Cured: Patient who presented a negative smear 
microscopic result at the end of the fifth month of 
treatment and finished the remaining month(s) of 
treatment. 
Defaulted: Patient who after taking TB medications for 
one month abandoned for at least two months. 
Failed: Patient initially diagnosed with a new case of 
SPPT in whom acid fast bacilli was still present in 
his/her fifth month sputum control test. 
Died: Patient who died in the course of tuberculosis 
treatment. 
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Transferred out: Patient who started treatment at Nylon 
District Hospital but was transferred to another 
tuberculosis treatment centre before the end of his/
her treatment. 
Completed treatment: Patient who completed his/her 
6/8 months TB treatment without presenting his/her 
5th month sputum control test result. 
Chronic excretor: Patient diagnosed with relapse SPPT 
in whom acid fast bacilli was still present in his/her 
fifth month sputum control test. 
Study population and design: It is a retrospective study 
in which all TB patients with SPPT registered in the 
Nylon District Hospital centre for the diagnosis and 
treatment of TB from 2003 to 2005 were included. 
The TB register was reviewed for age, sex, place of 
residence, HIV status, current treatment and treatment 
history. 
Data analysis: Data was entered and analysed using 
SPSS 12.0 for Windows. Logistic regression was used 
to compare treatment outcomes between patients 
who did an HIV test and those who did not, as well 
as between HIV positive and HIV negative patients. 
Unadjusted and adjusted (for age, gender, health 
district of residence) Odds Ratios’ were reported. 
The Yates Chi-square tests was used to compare 
groups of categorical variables. The Fisher exact test 
(WINPEPI 2007 version 4.1) was also used to analyse 
the modifying effect of HIV status and treatment 
history as well as HIV status and health district of 
residence on treatment outcome. The independent 
sample t-test was used to compare mean ages. 
 A 95% confidence interval was calculated and 
values of P < 0.05 were considered significant. 
RESULTS
A total of 427 patients were registered as having SPPT 
from 2003 to 2005. Three patients with combined SPPT 
and EPT and four patients with inconclusive HIV 
results were excluded from the analysis. Therefore 
we present the results of 420 patients. 
Patient characteristics: Of the 420 patients included in 
the analysis, 238(56.7%) were males. The median age 
was 30 years (range 13 to 74 years). Only 191(45.5%) 
of the patients live in the Nylon Health District. 
Three hundred and seventy three (88.8%) patients 
were adults aged 15 to 49 years. Up to 386(91.1%) 
out of the 420 patients took the HIV test. The patient 
characteristics of these 386 patients by HIV status are 
presented in Table 1. 
 There was no association between HIV status 
and neither health district of residence nor treatment 
history. However there was a significant association 
between HIV status and gender (P = 0.001) as well 
as age group (P = 0.0003). Of the 166 females with 
SPPT tested for HIV, 75(45.2%) were HIV positive as 
opposed to 61(27.7%) males of the 220 tested, giving 
a female to male SPPT/HIV co-infection ratio of 1.6. 
The mean age at diagnosis of patients with SPPT 
infected with HIV (33.59 ± 9.3 years) is similar (P = 
0.261,95% CI of the difference = -1.008 to 3.713) to 
that of SPPT patients negative for HIV (32.24 ± 12.2 
years). Up to 95(69.9%) of all SPPT/HIV co-infected 
patients were aged between 25 to 44 years. 
Table 1
Characteristics of SPPT patients by HIV status
Variable and  HIV+ (n=136) HIV- (n=250) Total per 
category  No.  (%) No.  (%) (T) category P-value 
Gender  
   Male  61   44.9 159   63.6 220 
   Female  75   55.1 91    36.4 166 0.001 
HD of residence 
   Nylon  54   39.7  120   48 174 
   Non Nylon 82   60.3  130   52 212  0.134 
Treatment history 
   New case  107  78.7 213   85.2 320 
   Old case  29   21.3  37    14.8  66  0.12 
Age group (years) 
   0-24  25   18.4  81    32.4  106 
   25-44  95   69.9  122   48.8  217 
   45+  16   11.7  47    18.8  63  0.0003 
P-value from Chi square with continuity correction. HD = Health District 
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Treatment outcome: Treatment results of the 420 
patients diagnosed with SPPT showed an overall 
cure rate of 69%, a default rate of 23.6%, a 3.3% 
death rate, a 2.9% treatment completion rate, a 
0.7% treatment failure rate and a transfer out rate 
of 0.5% (Table 2). 
As indicated in Table 3, the cure rate for SPPT cases 
was 78.8% for HIV-negative patients and 58.8% for 
HIV positive patients. SPPT/HIV co-infected patients 
were less likely to be cured (OR 0.384, 95%CI 0.250-
0.652) as compared to SPPT/HIV negative patients. 
The default rate for SPPT cases was 28.7% for HIV-
positive patients and 16.8% for HIV-negative patients. 
SPPT/HIV co-infected patients were more likely to 
default (OR 1.991, 95%CI 1.150-3.285) than SPPT/HIV-
negative patients. Likewise, the death rate of SPPT 
cases was 7.4% for HIV-positive patients and 0.4% 
for HIV -negative patients. SPPT/HIV co-infected 
patients were much more likely to die in the course 
of treatment [OR 19.759, 95%CI 2.894-194.330] than 
SPPT/HIV -negative patients. All these differences 
remained significant even after adjusting for age, 
gender, treatment history and residence. Treatment 
completion, treatment failure and transferred out 
were not associated with HIV status. 
Table 2
Treatment outcome for all patients
Aspect  Total  Cured Completed  Defaulted Died Failed Transferred
   treatment    out 
 No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
HIV Tested 386  100 277  71.8 12  3.1 81  21 11  2.8 3   0.8 2   0.5
 HIV positive 136  100 80   58.8  4   2.9 39  28.7 10  7.4 1   0.7 2   1.5   
 HIV negative 250  100 197  78.8  8   3.2 42  16.8 1   0.4 2   0.8 0   0
Not HIV tested 34   100 13   38.2 0   0 18  52.9 3   8.8 0   0 0   0
Total 420  100 290  69 12  2.9 99  23.6  14  3.3 3   0.7 2  0.5
Table 3
Treatment results for tuberculosis patients by HIV status showing adjusted and unadjusted Odds Ratios
      Non adjusted    Adjusted** 
Treatment Total HIV+ HIV-     
Results No. (%) No. (%) No. (%) OR* P-value 95%CI  OR* P-value 95%CI
Cured  277 71.8 80  58.8 197 78.8 0.384 <0.0001 0.243-0.607 0.404 0.0002 0.250-0.652
Completed
treatment 12  3.1  4   2.9 8   3.2 0.917 0.889 0.271-3.101 0.691 0.57 0.193-2.474
Defaulted 81  21  39  28.7 42  16.8 1.991 0.007 1.210-3.276 1.943 0.013 1.150-3.285
Died 11  2.8  10  7.4  1   0.4 19.759  0.005 2.502-156.104 23.714 0.003 2.894-194.330
Failed 3   0.8  1   0.7 2   0.8 0.919 0.945 0.083-10.223 0.657 0.749 0.051-8.553 
Transferred
out 2   0.5  2   1.5  0   0.0  *  * *  * *  *
Total 386 100 136 100 250 100 
*OR of treatment outcomes for SPPT cases for HIV-positive relative to HIV-negative patients. 
**Adjusted for age, gender, health district of residence and treatment history 
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Table 4
Treatment results for tuberculosis patients by HIV test acceptability showing adjusted and unadjusted Odds Ratios
  Not    Non adjusted    Adjusted$
  HIV HIV
Treatment Total Tested  Tested        
Result No. (%) No. (%) No. (%) OR£ P-value 95%CI OR£ P-value 95%CI   
   
Cured 290  69 13  38.2 277  71.8 0.244 <0.0001 0.118-0.504 0.21 <0.0001 0.099-0.445
Completed 
treatment 12   2.9 0   0.0 12  3.1 * * * * * *
Defaulted 99   23.6 18  52.9 81  21 4.236 <0.0001 2.069-8.673 4.773 <0.0001 2.281-9.991
Died 14   3.3 3   8.8 11  2.8 3.299 0.078   0.874-12.451 3.357 0.079 0.870-12.451
Failed 3    0.7 0   0.0 3   0.8  *  * * * * * 
Transferred
Out 2    0.5 0   0.0 2   0.5  * * * * *  *
Total 420 100 34 100 386 100 
£OR of treatment outcomes for SPPT cases for non HIV tested patients relative to HIV tested 
patients. $Adjusted for age, gender, health district of residence and treatment history 
Treatment outcome was associated with HIV status 
for SPPT patients resident in Nylon Health District 
(P= 0.0196) as well as non residents (P = 0.0002). 
 The cure rate (63% versus 56.1%), default rate 
(25.9% versus 30.5%) death rate (5.6% versus 8.5%) 
and treatment failure rate (0% versus 1.2%) for 
SPPT/HIV positive patients resident in NHD was 
more favorable compared to the same group of non 
Nylon residents respectively. 
 Likewise treatment outcome of SPPT was 
associated with HIV status both for new cases of 
TB (P = 0.0006) and for cases of relapse (P = 0.0056). 
The cure rate (59.8% versus 55.2%) and death rate 
(6.6% versus 10.3%) in co-infected new SPPT cases 
was more favorable compared to relapse co-infected 
SPPT cases. Meanwhile co-infected relapse patients 
had a better outcome when it came to default rate 
(27.6% versus 29%) and treatment failure (0% versus 
0.9%). 
 The cure rate for SPPT patients tested for HIV 
was 71.8% as opposed to 38.2% for SPPT patients 
not tested for HIV. SPPT patients not tested for HIV 
were less likely to be cured [OR 0.244, 95%CI 0.099-
0.445] compared to SPPT patients tested for HIV. 
The default rate for SPPT patients was 21% for those 
tested for HIV and 52.9% for those not tested for HIV. 
SPPT patients not tested for HIV were more likely 
to default [OR 4.236, 95%CI 2.281-9.991] than those 
tested. After adjusting for age, sex, residence and 
treatment history, the differences in cure rate and 
default rate remained significant (Table 4). The other 
treatment outcomes were not significantly associated 
with HIV test acceptability. 
DISCUSSION
The prevalence of HIV infection among SPPT patients 
in our study was 35.2%. We found that in patients 
with SPPT, HIV status was associated with gender 
and age. Women and adults aged 25 to 45 years were 
the most SPPT/HIV co-infected. The overall cure rate, 
default rate and death rate were 69%, 23.6% and 3.3% 
respectively. SPPT/HIV co-infected patients were 
significantly more likely to default from treatment, 
to die in the course of treatment or not to be cured 
compared to SPPT /HIV negative patients. Likewise 
SPPT patients not tested for HIV were significantly 
less cured and defaulted most compared to SPPT 
patients tested for HIV. 
 According to the third Demographic Health 
Survey (DHS III) of 2004 in Cameroon, the 
prevalence of HIV in the general population increases 
progressively from the age of 15 years and reaches 
a maximum of 10.3% in women aged 25 to 39 years 
and 8.6% in men aged 35 to 39 years (13). These age 
groups are amongst the most co-infected in our study. 
Also, the modifying effect of HIV to the TB-gender 
association is also related to the higher prevalence of 
HIV infection in women (6.8%) as opposed to men 
(4.1%) in the general population as reported in the 
DHS III. Therefore, supporting the fact that HIV is a 
very potent risk factor for TB, either by increasing the 
risk of direct progression of primary disease to full 
blown disease or increasing the risk of reactivating 
latent bacilli (14). 
 The female to male SPPT/HIV co-infection ratio 
of 1.6 in our study is similar to the female: male HIV 
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ratio of 1.7 in the general population as in the DHS III 
(13). Other common grounds between our TB/HIV 
co-infection study and the HIV study of the DHS III 
are the similar age group distribution in SPPT/HIV co-
infection and HIV infection in the general population 
and the female dominance in HIV infection as well 
as SPPT/HIV infection. Thus, in a country where 
surveys are scarcely done, a reflection needs to be 
carried out on the use of SPPT/HIV co-infection rate 
as a proxy for the estimation of HIV prevalence in 
some areas of the country. 
 The overall cure rate of 69% in our study is 
slightly higher than the 61% obtained by Banerjee 
and colleagues in Ntcheu District hospital in Malawi 
(7) but lower than the 76% found by Van den Broek 
et al in Mwanza Tanzania (6) and 77% by EI Sony 
et al in Sudan (5). This may be due to the fact that 
we used self-administered treatment as from day 
one except in severely ill patients who were treated 
as in-patients and discharged as soon as they got 
better. All the cited studies treated their patients 
with DOTS during the intensive phase and then 
ambulatory treatment during the continuation phase. 
The significantly higher cure rate of SPPT/HIV 
negative patients (but lower than the recommended 
85%) compared to SPPT/HIV positive ones in our 
study was common to all the above settings and of 
almost similar proportions (5-7). Meanwhile Murray 
and colleagues (4) studying miners in South Africa 
found similar cure rates between TB/HIV positive 
(89%) and TB/HIV negative (88%) patients under 
very strict, regular follow-up and well organised 
programme conditions after excluding death cases. 
 Tuberculosis patients tested for HIV had a 
far better outcome compared to their non tested 
counterparts because they benefited from an 
integrated care package especially those with a 
positive result. The non tested ones either were very 
sick to be counselled, presented at a terminal phase 
or refused the test. As such they died in the course 
of treatment or defaulted because they did not offer 
the team the opportunity to manage them in their 
entirety. Similar findings were reported by Banerjee 
and colleagues in Malawi (7). 
 Our overall death rate of 3.3% is very small just 
as the default rate of 23.6% is very high compared 
with other studies (4,6,7). This is probably due to an 
underestimation of the number of deaths. We did 
not put in place a system to identify the residence of 
patients or to actively search for those who abandoned 
their treatment. Most of the known dead cases die 
in the hospital for one reason or another. It is thus 
likely that a good proportion of the defaulted patients 
are likely dead cases. We also confirmed the high 
case fatalities in TB/HIV co-infected patients earlier 
reported by many authors (4-9). 
 Nylon residents had a better outcome because 
the HIV programme ran in the same hospital at the 
beginning would preferably enroll HIV positive 
patients living within the district and refer the 
others to the nearest treatment centres around their 
residents. Hence Nylon patients started benefiting 
from integrated care early enough while the others 
had to spend further time to adapt and be incorporated 
to other treatment sites. Distance would not explain 
the difference because locomotion is not a problem 
in a metropolitan city like Douala. 
Strengths and limitations: This paper is a follow-up 
to our previous publication on the prevalence of the 
HIV virus infection among tuberculosis patients in 
the Nylon District Hospital tuberculosis treatment 
centre (15). It goes further to emphasize the rates of 
the various TB treatment outcomes in HIV positive 
versus HIV negative patients and HIV tested versus 
HIV non tested patients. It also brings forth the 
importance of an integrated patient care approach in 
TB and HIV programmes in order to attain the 85% 
cure rate target recommended by WHO. 
 Our data did not permit us to do survival analysis 
which would have permitted us to better appreciate 
the treatment outcome especially the mortality rates 
of the various groups. Also, the number of cases for 
some treatment outcome categories were small giving 
very wide or incalculable confidence intervals. 
 DOTS per say wasn’t used in our setting because 
of the absence of the necessary logistics and human 
resources. Nonetheless an analysis to determine 
when patients abandoned treatment showed that 
there was no significant difference in the number of 
patients who defaulted before (intensive phase) or 
after (continuation phase) their first sputum control 
test (at the end of the second month of treatment).
In conclusion, SPPT/HIV co-infected patients 
significantly die more in the course of treatment, 
default more from treatment and are less likely to 
be cured from TB compared to SPPT/HIV negative 
patients. In the same way, SPPT patients not tested 
for HIV are significantly less cured and defaulted 
most compared to SPPT patients tested for HIV. 
In this light we therefore recommend that, not 
only should a system of active search for lost to 
follow-up patients be put to place, health personnel 
prescribing anti- TB drugs be provided with the 
necessary expertise to diagnose and manage HIV 
so that TB/HIV co-infected patients benefit from 
an integrated package of care in and out of the 
hospital. TB patients who refuse to do the HIV test 
or whose state of health does not permit them to be 
counselled should be considered HIV positive until 
proven otherwise. 
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